Sort   by:  
 Page size 
UnknownTRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Not available
S-EPMC4240732 | biostudies-literature
UnknownCOVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary.
Not available
S-EPMC8108433 | biostudies-literature
UnknownMultimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot.
Not available
S-EPMC10729108 | biostudies-literature
UnknownPrognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Not available
S-EPMC5042025 | biostudies-literature
UnknownAssociation of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Not available
S-EPMC6743060 | biostudies-literature
UnknownEfficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Not available
S-EPMC11443580 | biostudies-literature
UnknownPrognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
Not available
S-EPMC8852707 | biostudies-literature
UnknownCOVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Not available
S-EPMC7255715 | biostudies-literature
UnknownPersistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.
Not available
S-EPMC9040509 | biostudies-literature
UnknownSpecialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective.
Not available
S-EPMC8419540 | biostudies-literature
Sort   by:  
 Page size